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Background. In well treated human immunodeficiency virus infection (HIV), there is a residual immune activation and im-
mune exhaustion that may contribute to increased risk of comorbidities. T-cell immunoglobulin mucin domain-3 (Tim-3) is an 
inhibitory molecule involved in HIV-associated T-cell dysfunction. The Tim-3 can be cleaved to soluble Tim-3 (sTim-3) that may 
serve as a soluble marker of immune exhaustion.
Methods. We measured sTim-3 with enzyme-linked immunosorbent assay DuoSets in a cross-sectional cohort of 1010 
people with HIV (PWH) on antiretroviral therapy (ART), and 76 controls from the Copenhagen Co-Morbidity in HIV Infection 
(COCOMO) study, and in a longitudinal cohort of 60 PWH before and during ART.
Results. In the cross-sectional cohort, levels of sTim-3 were elevated in PWH on ART compared with controls, especially in hep-
atitis C virus (HCV)-coinfected individuals, and were associated with HCV viremia and inflammation. In the longitudinal cohort, 
pretreatment sTim-3 correlated with HIV viral load and decreased after ART initiation. Pretreatment sTim-3 correlated inversely 
with CD4 counts, but it did not predict immunological response in multivariable analyses.
Conclusions. Levels of sTim-3 decreased after ART initiation. In a cross-sectional cohort, levels of sTIM-3 were higher in PWH 
than in controls and were independently associated with HCV coinfection and high-sensitivity C-reactive protein, representing a 
potential link between immune exhaustion, inflammation, and risk of comorbidities.
Keywords.  hepatitis C; HIV; immune exhaustion; soluble; Tim-3.
Despite the success of antiretroviral therapy (ART), people with 
human immunodeficiency virus (PWH) have excess morbidity 
[1, 2]. Even when viral replication is undetectable in plasma 
due to ART, the body is unable to completely clear the virus, 
and the latent reservoir with low-grade viral replication could 
contribute to a state of persistent immune activation [3]. This 
nonresolving low-grade immune activation may induce T-cell 
exhaustion and immunosenescence, which could contribute to 
the increased burden of comorbidities such as non-acquired 
immune deficiency syndrome (AIDS)-defining cancer and 
metabolic and cardiovascular diseases (CVD) in PWH [4–6].
T cells contribute to clearance of viral infections, but they 
may turn into exhausted T cells when they are unable to clear 
viral reservoirs, like in chronic human immunodeficiency virus 
(HIV) infection, with harmful effects on the host due to per-
sistent low-grade antigen exposure [7]. In this process, several 
inhibitory molecules and receptors (checkpoint inhibitors) are 
upregulated, such as T-cell immunoglobulin and mucin do-
main-3 (Tim-3) and programmed cell death protein-1 (PD-1), 
probably to prevent persistent (too long) and overshooting (too 
high) T-cell activation, which could harm the host [4, 7].
Human Tim-3 is a transmembrane protein that is expressed 
on T cells and monocytes [8]. The Tim-3 is shown to play a 
modulating role in HIV-associated T-cell dysfunction [9], and 
the expression of Tim-3 seems to be a reliable marker of T-cell 
exhaustion in disorders characterized by persistent T-cell acti-
vation including chronic viral infection [10]. The Tim-3 can be 
cleaved from the cell surface by certain matrix metalloproteinases 
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(ie, A disintegrin and metalloprotease [ADAM]-10 and ADAM-
17) to a soluble form [11]. Although the function of soluble 
Tim-3 (sTim-3) is not clarified, it seems to reflect the degree of 
membrane expression of this checkpoint inhibitor. Therefore, 
sTim-3 could be an attractive soluble marker of persistent T-cell 
activation and exhaustion in various disorders including HIV 
[12].
To this end, data on sTim-3 in HIV infection are scarce and 
restricted to relatively small cohorts (n < 100) [13], with only 1 
reporting regulation of sTim-3 during ART [12]. We aimed to 
investigate sTim-3 in relation to clinical, immunological, and 
virologic characteristics in 2 well defined cohorts: (1) a large 
cross-sectional cohort of 1010 PWH and (2) a longitudinal 
study of 60 PWH initiating ART.
METHODS
Study Design and Populations
Cross-Sectional Cohort
A total of 1099 PWH and 78 controls from the general pop-
ulation were included from the Copenhagen Co-Morbidity 
in HIV Infection (COCOMO) study, which is a prospec-
tive study evaluating the burden of comorbidities in PWH in 
Copenhagen, Denmark. Inclusion criteria for the COCOMO 
study were a positive HIV test and age >18 years. Data collec-
tion was performed between March 2015 and November 2016. 
The procedures for recruitment and data collection have been 
described elsewhere [14]. Of 1099 participants and 78 con-
trols from the general population included in the COCOMO 
study, 1010 participants received ART and had available plasma 
samples and 76 controls where plasma samples were available 
were included in the present study. Sixty-six immunological 
nonresponders ([INRs] CD4 <350 × 106/L) and 133 immuno-
logical responders ([IRs] CD4 >500 × 106/L) matched on sex, 
age, time with HIV, CD4, and nadir CD4 cell counts were iden-
tified from the COCOMO study for subanalyses.
Longitudinal Study
Sixty PWH were included in a prospective study, and plasma 
samples were obtained before initiation of ART, and at 6 and 
12  months thereafter. All individuals were included from the 
Department of Infectious Diseases, Rigshospitalet, Copenhagen 
University Hospital, and Department of Infectious Diseases, 
Hvidovre Hospital as described previously [15].
Biochemistry
Nonfasting venous blood for plasma samples (ethylenedia-
minetetraacetic acid-anticoagulated) were immediately stored on 
ice until centrifugation at 4°C, before storing at −80°C. Soluble 
Tim-3 was analyzed by enzyme immunoassay using DuoSets 
(catalog no. DY2365) from R&D Systems (Stillwater, MN) in a 
384 format using a combination of a SELMA (Jena, Germany) 
pipetting robot and a BioTek (Winooski, VT) dispenser/washer. 
In brief, high binding 384-well microtiter plates (UltraCruz; 
Santa Cruz Biotechnology, Heidelberg, Germany) were coated 
with 20  μL 2  μg/mL primary antibody (part no.  843115)  in 
phosphate-buffered saline (PBS). Plates were washed 3 times 
(wash buffer 0.05% tween in PBS, wash similar for all washing 
steps) and blocked with 80 μL 1% bovine serum albumin (BSA) 
in PBS for >1 hour. Plates were washed again, and samples (di-
luted 50 times in 0.5% BSA in wash buffer) and standards were 
added in parallel and incubated overnight at 4oC. The following 
morning, plates were washed and 20  μL secondary antibody 
(20 μg/mL, part no. 843116) was added and incubated at room 
temperature for 2 hours. Plates were washed again, and 20  μL 
streptavidin-horseradish peroxidase (part no. 890803) was added 
and incubated for 20 minutes at room temperature. A final wash 
was performed, and 20 μL stable TMB solution was added (cat-
alog no. SB02; Life Technologies) and incubated for 10 minutes 
before 50  μL 1N H2SO4 was added, and absorption was read 
at 450  nm with wavelength correction set to 540  nm using a 
Synergy H1 plate reader (BioTek). Intra- and interassay coeffi-
cients of variation were <10%. Sensitivity, defined as 3×SD of a 
low sample, was 36 pg/mL. Average parallelity of 3 samples se-
rially diluted 5 times was 113%, average recovery of 2 samples 
spiked with low and high sTim-3 was 111%, whereas average 
level of 4 samples exposed to 2–10 freeze-thaw cycles was 104%. 
Plasma high-sensitivity C-reactive protein (hsCRP) was ana-
lyzed at Biochemical Department, Herlev University Hospital, 
Copenhagen as previously described [14].
Statistical Analysis
Differences in continuous variables with normal distribution 
were compared using Students t test, whereas skewed variables 
were compared using Mann-Whitney U test. Due to differences 
in age and sex between groups, sTim-3 levels were compared 
using multivariable regression, using group as a fixed factor and 
age and sex as covariate. These data are expressed as estimated 
marginal means and 95% confidence intervals. In the paired sit-
uation, levels were first compared with the Friedman test and, if 
significant, Wilcoxon paired test was used to compare changes in 
sTim-3 levels between different time points. Categorical variables 
were compared with χ 2 test. Correlations were investigated using 
Spearman rank-order test, and multivariable analyses were per-
formed by linear regression, predicting sTim-3 levels after adjust-
ment for relevant covariates (current CD8 count, nadir CD4 count, 
age, hsCRP, estimated glomerular filtration rate (eGFR), smoking, 
previous AIDS-defining diagnosis, and hepatitis C coinfection).
SPSS software and GraphPad Prism were used for the sta-
tistical analysis. A  2-sided P < .05 was considered statistically 
significant.
Ethical Aspects
All patients gave written informed consent before storage of blood 
samples. The study was approved by the Scientific Ethics Committee 
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of the Capital Region of Denmark (protocol H-15017350 and H-2-
2011-089), the Danish Data Protection Agency (jr.nr 30-1454), and 
the Regional Committees for Medical and Health Research Ethics 
in Norway (2018/2565-1). All processing of personal data followed 
national guidelines and regulations.
RESULTS
Clinical Characteristics
The characteristics of the 2 cohorts are shown in Tables 1 and 
2. The cross-sectional study consisted of 1010 PWH on stable 
ART with available sTIM-3 measurements and 76 controls from 
the general population. The median age was 50 years for PWH 
(85% male) and 60 years for controls (69% male). Median nadir 
CD4 count was 235 cells/µL, current median CD4 count was 
690 cells/µL, and 18% had a previous AIDS-defining diagnosis. 
In addition, 11% were anti-hepatitis C virus (HCV) positive, 6% 
were coinfected with active HCV infection (detectable plasma 
HCV ribonucleic acid [RNA]), whereas 4% were hepatitis B 
surface antigen positive (Table 1).
In the longitudinal study with 60 PWH, the median age was 
40 years (92% male), and the median CD4 count and viral load 
before ART initiation were 380 cells/µL and 80 919 RNA copies/
mL, respectively (Table 2).
Levels of Soluble T-Cell Immunoglobulin Mucin Domain-3 During Stable 
Antiretroviral Therapy: The Cross-Sectional Study
Figure 1A shows the distribution of sTim-3 in PWH and con-
trols. The PWH cohort was younger and with a higher per-
centage of males, but in multivariable regression analysis 
adjusting for age and sex significantly higher sTim-3 levels was 
found in PWH compared with controls (P < .001) (Figure 1B). 
The difference remained significant after excluding the 55 indi-
viduals with HCV coinfection (P < .001).
In PWH, sTim-3 correlated positively with age, hsCRP, time since 
HIV diagnosis, time on ART, previous AIDS diagnosis, past and 
present smoking, and HCV serostatus and negatively with nadir 
CD4 T-cell counts and eGFR (Table 1). In contrast, age did not cor-
relate with sTim-3 in the control group (rho = −0.05, P = .97).
Coinfection With Hepatitis C Is Associated With Elevated Soluble T-Cell 
Immunoglobulin Mucin Domain-3 Levels: Cross-Sectional Study
Because sTim-3 correlated with HCV serostatus, we analyzed a 
subset of 55 PWH who were coinfected with HCV (detectable 
Table 1. Baseline Characteristics of Cross-Sectional Cohort
Cross-Sectional Cohort
Correlation With  
sTim-3
Regression With 
sTim-3 as Dependent
PWH (n = 1010) rho P β P
Age, years, median (IQR) 50 (43–58) 0.26 0.000 0.15 0.004
Sex, male, % 85 −0.06 0.068   
Mode of transmission, % (n)      
 MSM 71.0 (712)     
 Heterosexual 22.0 (216)     
 PWID 1.4 (14)     
 Other 5.6 (58)     
Current viral load <50, % (n) 95.2 (952)     
Nadir CD4, cells/µL, median (IQR) 235 (120–350) −0.08 0.016 0.01 0.882
CD4, cells/µL, median (IQR) 690 (520–890) −0.00 0.977   
CD8, cells/µL, median (IQR) 840 (632–1188) 0.07 0.029 0.01 0.867
Viral load, copies/mL, median (IQR) 19 (19–20) −0.01 0.653   
hsCRP, mg/L, median (IQR) 1.2 (0.6–2.5) 0.24 0.000 0.18 0.000
eGFR, mL/min/1.73m2, mean (SD) 89 (15.4) −0.25 0.000 −0.16 0.001
Anti-HCV positive % (n) 10.5 (103) 0.10 0.002   
HCV RNA positive % (n) 6 (55) 0.11 0.001 0.14 0.000
HBsAg positive % (n) 3.7 (37) 0.04 0.197   
Anti-HBc positive % (n) 5.7 (50) 0.02 0.483   
Anti-HBs positive % (n) 70.2 (702) 0.01 0.657   
CD4/CD8 median (IQR) 0.81 (0.57–1.13) −0.06 0.065   
CDC AIDS (past) 18 (184) 0.08 0.008 0.02 0.654
sTim-3 ng/mL, median (IQR) 7.0 (5.8–8.8)     
Time since diagnosis, years, median (IQR) 13.7 (6.9–21.3) 0.15 0.000   
Time on ART, years, median (IQR) 10.5 (5.2–17.0) 0.14 0.000   
Smoking, packyears in current and previous smokers, median (IQR) 18.8 (7.0–32.0) 0.19 0.000 0.07 0.103
Abbreviations: ART, antiretroviral therapy; CDC AIDS, Center for Disease Control and Prevention AIDS-defining conditions; eGFR, estimated glomerular filtration rate; HBc, hepatitis B core 
antibody; Hbs, hepatitis B surface antibody; HbsAg, hepatitis B surface antigen; HCV, hepatitis C virus; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range; MSM, men whom 
have sex with men; PWH, people with human immunodeficiency virus; PWID, people who inject drugs; RNA, ribonucleic acid; SD, standard deviation; sTim-3, soluble T-cell immunoglobulin 
mucin domain-3.
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HCV RNA in plasma). As shown in Figure 1C, sTim-3 levels 
were significantly higher in PWH with HCV coinfection (me-
dian, 8.1  ng/mL; interquartile range [IQR], 6.3–10.2  ng/mL) 
than in PWH without HCV coinfection (median, 7.0  ng/mL; 
IQR, 5.7–8.7 ng/mL) (P = .001).
Predictors of Soluble T-Cell Immunoglobulin Mucin Domain-3 in People 
With Human Immunodeficiency Virus: Cross-Sectional Study
Linear regression was used to assess predictors of sTim-3 in 
PWH. Nadir CD4 counts, CD8 counts, age, hsCRP, eGFR, 
previous AIDS-defining diagnosis, cumulative tobacco pack-
years, and presence of HCV RNA were included as variables 
in a multivariable analysis with sTim-3 as the dependent vari-
able. Hepatitis C viremia (β = 0.14, P < .001), hsCRP (β = 0.20, 
P < .001), low eGFR (β = −0.17, P < .001), and age (β = 0.17, 
P < .001) were associated with higher sTim-3 (Table  1). Of 
the 55 coinfected with HCV, 4 were people who inject drugs 
(PWID). The PWID status (n = 14) was correlated with sTIM-3 
(rho = 0.088, P = .006), but it did not predict sTim-3 in the 
multivariable regression analysis in the total cohort.
Levels of Soluble T-Cell Immunoglobulin Mucin Domain-3 in Relation to 
Viral Load Before and During Antiretroviral Therapy: Longitudinal Study
In the longitudinal cohort, there was a significant decrease of 
38% in sTim-3 after initiating ART (median, 9.2 ng/mL; IQR, 
6.0–12.4  ng/mL) with stabilized levels at 6 (median, 5.8  ng/
mL; IQR, 4.4–7.2  ng/mL) and 12 (median, 5.8  ng/mL; IQR, 
4.4–7.4 ng/mL) months of follow up (Figure 2A). Furthermore, 
baseline sTim-3 correlated with baseline viral load (median 
load, 80 919 copies/mL; rho = 0.51; P < .001) and sTim-3 after 
6  months correlated with viral load after 6  months (median 
load, 20 copies/mL; rho = 0.29; P = .048).
Soluble T-Cell Immunoglobulin Mucin Domain-3 Is Associated With 
Pre-Antiretroviral Therapy (ART) CD4 Counts, but Not With Immune 
Reconstitution During ART: Cross-Sectional and Longitudinal Study
Next, we aimed to investigate whether sTim-3 could predict 
immune reconstitution during ART. In the longitudinal co-
hort, baseline sTim-3 correlated inversely with nadir and base-
line CD4 counts and with CD4 counts 6 and 12 months after 
ART initiation (Figure 2B). However, in a multivariable linear 
regression with CD4 counts 12 months after ART initiation as 
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Figure 1. Levels of soluble T-cell immunoglobulin mucin domain-3 (sTim-3) in cross-sectional cohort. (A) Distribution of sTim-3 in people with human immunodeficiency 
virus (PWH) and controls (CTR). (B) Levels of sTim-3 in PWH and noninfected CTR. (C) Levels of sTim-3 in PWH with and without hepatitis C virus (HCV). Data in B and C are 
presented as estimated marginal means and 95% confidence intervals, adjusted for age and sex.
Table 2. Characteristics of Longitudinal Cohort
Characteristics Longitudinal Cohort (n = 60)
 Baseline 6 Months After ART 12 Months After ART
Age, years, median (IQR) 40 (33–47)   
Sex 92% male   
Nadir CD4, cells/µL, median (IQR) 370 (239–520)   
CD4, cells/µL, median (IQR) 380 (239–537) 600 (430–750) 610 (450–770)
CD8, cells/µL, median (IQR) 1000 (525–1500) 920 (680–1400) 970 (640–1300)
Viral load, copies/mL, median (IQR) 80 919 (30 059–328 245) 20 (19–30) 20 (19–20)
CD4/CD8 median (IQR) 0.34 (0.23–0.52) 0.60 (0.32–0.92) 0.63 (0.31–0.92)
sTim-3 ng/mL, median (IQR) 9.3 (6.0–12.4) 5.8 (4.4–7.2) 5.8 (4.4–7.4)
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range; sTim-3, soluble T-cell immunoglobulin mucin domain-3.
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dependent variable, only nadir CD4 count (β = 0.82, P < .001) 
but not baseline sTim-3 (β = 0.06, P = .526) predicted CD4 
counts after 12 months.
Finally, in a subanalysis of the cross-sectional cohort 
with 66 INRs (CD4 <350  ×  106/L) and 133 matched IRs 
(CD4 >500  ×  106/L), we found no significant difference in 
sTim-3 between INR (median, 7.6 ng/mL; IQR, 6.1–9.5 ng/mL) 
and IR (median, 6.9 ng/mL; IQR, 5.6–8.8 ng/mL) (P = .074).
DISCUSSION
Dysregulation of coinhibitory molecules plays a role in T-cell 
dysfunction and persistent immune activation in HIV infec-
tion. In the present study, we aimed to explore the levels of 
sTim-3 in relation to HIV-specific parameters, coinfections, 
and demographic parameters as well as its response to ART. 
Our main findings can be summarized as follows: (1) in a large 
cross-sectional study, levels of sTim-3 were elevated in PWH 
on ART compared with controls; (2) in a longitudinal study, 
levels of sTim-3 correlated with HIV viral load before treat-
ment and decreased after initiation of ART; (3) in the cross-sec-
tional study, coinfection with HCV and systemic inflammation 
as assessed by hsCRP predicted sTim-3 in linear regression 
analysis; and (4) in the longitudinal study, baseline sTim-3 
correlated inversely with nadir and baseline CD4 counts, and 
with CD4 counts 6 and 12 months after ART initiation, but in 
multivariable analyses, sTim-3 did not predict immunological 
response after ART initiation.
Previous studies have reported elevated levels of Tim-3 ex-
pression on T cells in untreated HIV infection, increasing 
levels with progressive disease, and reduced Tim-3 levels in pa-
tients receiving ART [8, 16, 17], but data on sTIM-3 before and 
after initiation of ART are scarce. A  decrease of sTim-3 after 
initiating ART has been shown during primary HIV infection 
[12]. In our longitudinal cohort of patients with chronic HIV 
infection, we found that sTim-3 levels correlated with viral load, 
nadir, and current CD4 counts after 6 months of ART. In ad-
dition, we found that sTim-3 decreased after ART initiation. 
Moreover, whereas similar sTim-3 levels in PWH on ART and 
healthy controls have been reported in a small group of patients 
(n = 20) [13], we show in a large cross-sectional study that 
PWH (n = 1010) had higher levels of sTim-3 compared with 
HIV-noninfected controls even after several years on suppres-
sive ART. Thus, even in patients on stable ART, sTim-3 is ele-
vated compared with controls, suggesting a degree of immune 
exhaustion even in these patients, but the overlap between 
PWH on ART and controls suggests that it is difficult to use 
sTim-3 as a specific marker of exhaustion.
People with HIV coinfected with HCV are at higher risk of 
comorbidities such as diabetes and liver, kidney, and CVD, pos-
sibly linked to immune activation [18, 19]. Data on Tim-3 ex-
pression on CD8 T cells in PWH that are coinfected with HCV 
have previously been somewhat contradictory [20, 21]. We 
show that PWH on ART that were coinfected with HCV had 
even higher sTim-3 levels than PWH without HCV infection, 
and notably HCV viremia was one of the strongest predictors of 
high sTim-3 levels. This may give additional explanation to the 
increased risk of comorbidities in coinfected patients. Our data 
suggest that these coinfected individuals have an ever higher de-
gree of T-cell exhaustion and persistent immune activation and 
underscore the need for treating both infections in PWH that 
are coinfected with HCV. With the new direct-acting antivirals 
and cure rates comparable to HCV monoinfected individuals, 
the main challenge is to identify patients and to prevent reinfec-
tion in high-risk groups [22].
In HIV, immune exhaustion is linked to comorbidities 
even in patients on ART and represents a potential obstacle 
for a cure [4]. In the cross-sectional study, we found a strong 
correlation between hsCRP and sTim-3, reflecting persistent 
inflammation and immune exhaustion as 2 faces of the 
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Figure 2. Levels of sTim-3 in longitudinal cohort. (A) Soluble T-cell immunoglobulin mucin domain-3 (sTim-3) before initiation of antiretroviral therapy ([ART] baseline [BL]) 
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ART. Spearman correlation test.
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dysregulated immunity in HIV even on stable ART. High-
sensitivity CRP is linked to aging, immunoscenescense, mor-
bidity, and mortality in PWH [5, 23–25], and future studies 
should examine whether the combination of these markers 
(sTim-3 and hsCRP) could give even more prognostic in-
formation in PWH. Lipopolysaccharides may contribute 
to Tim-3 upregulation and shedding [13], possibly linking 
immune exhaustion to microbial translocation, which also 
contributes to systemic immune activation in HIV [26], po-
tentially reflecting a complex interacting network that pro-
motes an accelerated aging in PWH.
Immunological nonresponders are PWH who fail to achieve 
optimal CD4 T-cell reconstitution after ART, and they have 
higher immune activation, increased risk of comorbidities, pro-
gression to AIDS, and higher mortality [25, 27, 28]. We aimed 
to explore the potential role of sTim-3 in these patients, but we 
did not find a difference in sTim-3 levels between IRs and INRs. 
In addition, although pre-ART sTim-3 was associated with 
CD4 counts 1 year after ART initiation, it did not predict CD4 
T-cell count in multivariate analyses. However, the number of 
patients in the longitudinal study was relative low, and future 
studies should examine the potential for checkpoint inhibitors 
in HIV therapy through enhancement of therapeutic vaccine 
responses, reversing latency, and through enhancing T-cell 
function to eliminate infected cells [29].
The strengths of this study are well defined cohorts, one with 
1010 participants, including 55 coinfected with HCV. However, 
we did not have baseline sTim-3 measurements in the cross-sec-
tional cohort, so the predictive value of baseline sTim-3 in this 
cohort (for example, on INR) is unknown. We did not have 
available peripheral blood mononuclear cells for further char-
acterization of immune function, which would have strength-
ened the study. Moreover, the noninfected control group was 
small (n = 76).
CONCLUSIONS
In conclusion, sTim-3 decreased after initiation of ART, but 
treated PWH had higher levels of sTim-3 than controls, with 
the highest levels in those coinfected with HCV. The correlation 
between hsCRP and sTim-3 might represent a link between 
immune activation and exhaustion in well treated PHW con-
tributing to the increased occurrence of comorbidities and ac-
celerated aging in these patients.
Acknowledgments
Author contributions. P. A., M. T., and S. D. N. were responsible for the 
study concept. S. D. N., T. B., H. U., H. J. H., M. G., and M. H.-S. were re-
sponsible for study design and inclusion of patients. T. U., H. H., and A. E. 
M. carried out the experiments. T. U., H. H., and M. T. did the statistical 
analyses. H. H., P. A., and M. T. drafted the manuscript. All coauthors par-
ticipated in discussions about the interpretation of the findings and criti-
cally reviewed the manuscript.
Financial support. This work was funded by South-Eastern Norway 
Regional Health Authorities (Grant 39819).
Potential conflicts of interest. S.  D. N.  reports grants from Novo 
Nordisk Foundation and Rigshospitalet Research Foundation, 
Advisory Board and traveling grant from Gilead, and Advisory Board 
for GSK, outside the submitted work. T. B.  reports grants from Pfizer, 
NovoNordisk Foundation, Simonsen Foundation, GSK, and personal 
fees from GSK, Pfizer, Boehringer Ingelheim, Gilead, and MSD, outside 
the submitted work. H. U. received an unrestricted research grant from 
Novartis, outside the submitted work. All authors have submitted the 
ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts 
that the editors consider relevant to the content of the manuscript have 
been disclosed.
References
1. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among 
HIV-infected persons compared with the general population. Clin Infect Dis 
2011; 53:1120–6.
2. Hasse B, Ledergerber B, Furrer H, et al.; Swiss HIV Cohort Study. Morbidity and 
aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 
53:1130–9.
3. Doitsh G, Galloway NL, Geng X, et al. Cell death by pyroptosis drives CD4 T-cell 
depletion in HIV-1 infection. Nature 2014; 505:509–14.
4. Khaitan  A, Unutmaz  D. Revisiting immune exhaustion during HIV infection. 
Curr HIV/AIDS Rep 2011; 8:4–11.
5. Sokoya T, Steel HC, Nieuwoudt M, Rossouw TM. HIV as a cause of immune acti-
vation and immunosenescence. Mediators Inflamm 2017; 2017:6825493.
6. Pathai S, Bajillan H, Landay AL, High KP. Is HIV a model of accelerated or accen-
tuated aging? J Gerontol A Biol Sci Med Sci 2014; 69:833–42.
7. Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections. 
Nat Immunol 2005; 6:873–9.
8. Jones RB, Ndhlovu LC, Barbour JD, et al. Tim-3 expression defines a novel pop-
ulation of dysfunctional T cells with highly elevated frequencies in progressive 
HIV-1 infection. J Exp Med 2008; 205:2763–79.
9. Sakhdari A, Mujib S, Vali B, et al. Tim-3 negatively regulates cytotoxicity in ex-
hausted CD8+ T cells in HIV infection. PLoS One 2012; 7:e40146.
10. Jin HT, Anderson AC, Tan WG, et al. Cooperation of Tim-3 and PD-1 in CD8 
T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A 2010; 
107:14733–8.
11. Möller-Hackbarth  K, Dewitz  C, Schweigert  O, et  al. A disintegrin and 
metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T 
cell immunoglobulin and mucin domain 3 (Tim-3). J Biol Chem 2013; 
288:34529–44.
12. Zilber E, Martin GE, Willberg CB, et al.; CHERUB Investigators. Soluble plasma 
programmed death 1 (PD-1) and Tim-3 in primary HIV infection. AIDS 2019; 
33:1253–6.
13. Clayton KL, Douglas-Vail MB, Nur-ur Rahman AK, et al. Soluble T cell immuno-
globulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, 
is increased in plasma during untreated HIV infection, and correlates with HIV 
disease progression. J Virol 2015; 89:3723–36.
14. Ronit  A, Haissman  J, Kirkegaard-Klitbo  DM, et  al. Copenhagen comorbidity 
in HIV infection (COCOMO) study: a study protocol for a longitudinal, non-
interventional assessment of non-AIDS comorbidity in HIV infection in 
Denmark. BMC Infect Dis 2016; 16:713.
15. Hartling HJ, Jespersen S, Gaardbo JC, et al. Reduced IL-7R T cell expression and 
increased plasma sCD127 in late presenting HIV-infected individuals. J Acquir 
Immune Defic Syndr 2017; 74:81–90.
16. Kassu A, Marcus RA, D’Souza MB, et al. Suppression of HIV replication by antire-
troviral therapy reduces TIM-3 expression on HIV-specific CD8(+) T cells. AIDS 
Res Hum Retroviruses 2011; 27:1–3.
17. Rallón N, García M, García-Samaniego  J, et al. Expression of PD-1 and Tim-3 
markers of T-cell exhaustion is associated with CD4 dynamics during the course 
of untreated and treated HIV infection. PLoS One 2018; 13:e0193829.
18. Veenhuis  RT, Astemborski  J, Chattergoon  MA, et  al. Systemic elevation of 
proinflammatory interleukin 18 in HIV/HCV coinfection versus HIV or HCV 
monoinfection. Clin Infect Dis 2017; 64:589–96.
19. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical compli-
cations, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011; 
8:12–22.
20. Rallón N, García M, García-Samaniego J, et al. HCV coinfection contributes to 
HIV pathogenesis by increasing immune exhaustion in CD8 T-cells. PLoS One 
2017; 12:e0173943.
21. Feuth  T, Arends  JE, Fransen  JH, et  al. Complementary role of HCV and HIV 
in T-cell activation and exhaustion in HIV/HCV coinfection. PLoS One 2013; 
8:e59302.
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/article-abstract/7/2/ofaa033/5717191 by Faculty of Life Sciences Library user on 07 July 2020
Soluble Tim-3 in HIV Infection • ofid • 7
22. Bruno G, Saracino A. Direct-acting antivirals for HIV/HCV co-infected individ-
uals: as good as it gets? Curr HIV Res 2017; 15:422–33.
23. Kuller  LH, Tracy  R, Belloso  W, et  al.; INSIGHT SMART Study Group. 
Inflammatory and coagulation biomarkers and mortality in patients with HIV 
infection. PLoS Med 2008; 5:e203.
24. Wallet  MA, Buford  TW, Joseph  AM, et  al. Increased inflammation but similar 
physical composition and function in older-aged, HIV-1 infected subjects. BMC 
Immunol 2015; 16:43.
25. Vos  AG, Idris  NS, Barth  RE, et  al. Pro-inflammatory markers in relation to 
cardiovascular disease in HIV infection. a systematic review. PLoS One 2016; 
11:e0147484.
26. Brenchley  JM, Price  DA, Schacker  TW, et  al. Microbial translocation is a 
cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 
12:1365–71.
27. Lichtenstein  KA, Armon  C, Buchacz  K, et  al.; HIV Outpatient Study (HOPS) 
Investigators. Low CD4+ T cell count is a risk factor for cardiovascular disease 
events in the HIV outpatient study. Clin Infect Dis 2010; 51:435–47.
28. Piconi S, Trabattoni D, Gori A, et al. Immune activation, apoptosis, and Treg ac-
tivity are associated with persistently reduced CD4+ T-cell counts during antire-
troviral therapy. AIDS 2010; 24:1991–2000.
29. Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat 
Rev Immunol 2018; 18:91–104. D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/article-abstract/7/2/ofaa033/5717191 by Faculty of Life Sciences Library user on 07 July 2020
